SEARCH

SEARCH BY CITATION

References

  • 1
    Matsuzawa, Y., Funahashi, T., Nakamura, T. (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci. 892: 146154.
  • 2
    Scherer, P. E., Williams, S., Fogliano, M., Baldini, G., Lodish, H. F. (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 270: 2674626749.
  • 3
    Arita, Y., Kihara, S., Ouchi, N., et al. (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 257: 7983.
  • 4
    Weyer, C., Funahashi, T., Tanaka, S., et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 86: 19301935.
  • 5
    Yu, J. G., Javorschi, S., Hevener, A. L., et al. (2002) The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 51: 29682974.
  • 6
    Hu, E., Liang, P., Spiegelman, B. M. (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 271: 1069710703.
  • 7
    Kern, P. A., Di Gregorio, G. B., Lu, T., Rassouli, N., Ranganathan, G. (2003) Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression. Diabetes. 52: 17791785.
  • 8
    Statnick, M. A., Beavers, L. S., Conner, L. J., et al. (2000) Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res. 1: 8188.
  • 9
    Yang, W. S., Chen, M. H., Lee, W. J., et al. (2003) Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int J Obes Relat Metab Disord. 27: 896900.
  • 10
    Motoshima, H., Wu, X., Sinha, M. K., et al. (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab. 87: 56625667.
  • 11
    Fasshauer, M., Klein, J., Neumann, S., Eszlinger, M., Paschke, R. (2002) Hormonal regulation of adiponectin gene expression in 3T3–L1 adipocytes. Biochem Biophys Res Commun. 290: 10841089.
  • 12
    Clarke, K. J., Zhong, Q., Schwartz, D. D., Coleman, E. S., Kemppainen, R. J., Judd, R. L. (2003) Regulation of adiponectin secretion by endothelin-1. Biochem Biophys Res Commun. 312: 945949.
  • 13
    Fasshauer, M., Kralisch, S., Klier, M., et al. (2003) Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3–L1 adipocytes. Biochem Biophys Res Commun. 301: 10451050.
  • 14
    Mohlig, M., Wegewitz, U., Osterhoff, M., et al. (2002) Insulin decreases human adiponectin plasma levels. Horm Metab Res. 34: 655658.
  • 15
    Hirose, H., Kawai, T., Yamamoto, Y., et al. (2002) Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism. 51: 314317.
  • 16
    Yang, W. S., Jeng, C. Y., Wu, T. J., et al. (2002) Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 25: 376380.
  • 17
    Maeda, N., Takahashi, M., Funahashi, T., et al. (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50: 20942099.
  • 18
    Ishibashi, K. I., Imamura, T., Sharma, P. M., Huang, J., Ugi, S., Olefsky, J. M. (2001) Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3–L1 adipocytes. J Clin Invest. 107: 11931202.
  • 19
    Ferri, C., Bellini, C., Desideri, G., et al. (1997) Circulating endothelin-1 levels in obese patients with the metabolic syndrome. Exp Clin Endocrinol Diabetes. 2(Suppl 105): 3840.
  • 20
    Irving, R. J., Noon, J. P., Watt, G. C., Webb, D. J., Walker, B. R. (2001) Activation of the endothelin system in insulin resistance. QJM. 94: 321326.
  • 21
    Piatti, P. M., Monti, L. D., Galli, L., et al. (2000) Relationship between endothelin-1 concentration and metabolic alterations typical of the insulin resistance syndrome. Metabolism. 49: 748752.
  • 22
    Mather, K. J., Mirzamohammadi, B., Lteif, A., Steinberg, H. O., Baron, A. D. (2002) Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes. 51: 35173523.
  • 23
    Cardillo, C., Campia, U., Bryant, M. B., Panza, J. A. (2002) Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 106: 17831787.
  • 24
    Wilkes, J. J., Hevener, A., Olefsky, J. (2003) Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes. 52: 19041909.
  • 25
    Ottosson-Seeberger, A., Lundberg, J. M., Alvestrand, A., Ahlborg, G. (1997) Exogenous endothelin-1 causes peripheral insulin resistance in healthy humans. Acta Physiol Scand. 161: 211220.
  • 26
    Jiang, Z. Y., Zhou, Q. L., Chatterjee, A., et al. (1999) Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. Diabetes. 48: 11201130.
  • 27
    Imamura, T., Ishibashi, K., Dalle, S., Ugi, S., Olefsky, J. M. (1999) Endothelin-1-induced GLUT4 translocation is mediated via Galpha(q/11) protein and phosphatidylinositol 3-kinase in 3T3–L1 adipocytes. J Biol Chem. 274: 3369133695.
  • 28
    Ishibashi, K., Imamura, T., Sharma, P. M., Ugi, S., Olefsky, J. M. (2000) The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3–L1 adipocytes. Endocrinology. 141: 46234628.
  • 29
    DeFronzo, R. A., Tobin, J. D., Andres, R. (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237: E214E223.
  • 30
    Hafizi, S., Allen, S. P., Goodwin, A. T., Chester, A. H., Yacoub, M. H. (1999) Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the ET(A) receptor and is co-mitogenic with growth factors. Atherosclerosis. 146: 351359.
  • 31
    Maguire, J. J., Davenport, A. P. (1995) ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro. Br J Pharmacol. 115: 191197.
  • 32
    Bohm, F., Ahlborg, G., Pernow, J. (2002) Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci (Lond). 102: 321327.
  • 33
    Polak, K., Petternel, V., Luksch, A., et al. (2001) Effect of endothelin and BQ123 on ocular blood flow parameters in healthy subjects. Invest Ophthalmol Vis Sci. 42: 29492956.
  • 34
    Bohm, F., Pernow, J., Lindstrom, J., Ahlborg, G. (2003) ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clin Sci (Lond). 104: 143151.
  • 35
    Newby, D. E., Flint, L. L., Fox, K. A., Boon, N. A., Webb, D. J. (1998) Reduced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X. J Am Coll Cardiol. 31: 15851590.
  • 36
    Spratt, J. C., Goddard, J., Patel, N., Strachan, F. E., Rankin, A. J., Webb, D. J. (2001) Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol. 134: 648654.
  • 37
    Hotta, K., Funahashi, T., Arita, Y., et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 20: 15951599.
  • 38
    Yamamoto, Y., Hirose, H., Saito, I., et al. (2002) Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond). 103: 137142.